JP2021502379A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502379A5 JP2021502379A5 JP2020525974A JP2020525974A JP2021502379A5 JP 2021502379 A5 JP2021502379 A5 JP 2021502379A5 JP 2020525974 A JP2020525974 A JP 2020525974A JP 2020525974 A JP2020525974 A JP 2020525974A JP 2021502379 A5 JP2021502379 A5 JP 2021502379A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- duraglutide
- dose
- once
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022014339A JP7818412B2 (ja) | 2017-11-21 | 2022-02-01 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2024021637A JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589244P | 2017-11-21 | 2017-11-21 | |
| US62/589,244 | 2017-11-21 | ||
| PCT/US2018/060716 WO2019103875A2 (en) | 2017-11-21 | 2018-11-13 | Methods of using and compositions containing dulaglutide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022014339A Division JP7818412B2 (ja) | 2017-11-21 | 2022-02-01 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502379A JP2021502379A (ja) | 2021-01-28 |
| JP2021502379A5 true JP2021502379A5 (https=) | 2021-03-11 |
| JP7221956B2 JP7221956B2 (ja) | 2023-02-14 |
Family
ID=64572530
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020525974A Active JP7221956B2 (ja) | 2017-11-21 | 2018-11-13 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2022014339A Active JP7818412B2 (ja) | 2017-11-21 | 2022-02-01 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2024021637A Pending JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022014339A Active JP7818412B2 (ja) | 2017-11-21 | 2022-02-01 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
| JP2024021637A Pending JP2024056908A (ja) | 2017-11-21 | 2024-02-16 | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11576950B2 (https=) |
| EP (1) | EP3713593A2 (https=) |
| JP (3) | JP7221956B2 (https=) |
| KR (2) | KR102589234B1 (https=) |
| CN (2) | CN120478602A (https=) |
| AU (2) | AU2018372709B2 (https=) |
| BR (1) | BR112020007817A2 (https=) |
| CL (1) | CL2020001252A1 (https=) |
| CR (1) | CR20200202A (https=) |
| DO (1) | DOP2020000104A (https=) |
| EA (1) | EA202090971A1 (https=) |
| EC (1) | ECSP20026436A (https=) |
| IL (1) | IL274563B2 (https=) |
| JO (1) | JOP20200126B1 (https=) |
| MA (1) | MA50798A (https=) |
| MX (1) | MX2020005231A (https=) |
| PE (1) | PE20200847A1 (https=) |
| PH (1) | PH12020550795A1 (https=) |
| SG (1) | SG11202003687RA (https=) |
| UA (1) | UA127588C2 (https=) |
| WO (1) | WO2019103875A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020190591A1 (en) * | 2019-03-15 | 2020-09-24 | Eli Lilly And Company | Preserved formulations |
| KR20220132606A (ko) * | 2020-01-30 | 2022-09-30 | 일라이 릴리 앤드 캄파니 | 둘라글루티드의 치료 용도 |
| EP4153130A1 (en) * | 2020-05-19 | 2023-03-29 | F. Hoffmann-La Roche AG | The use of chelators for the prevention of visible particle formation in parenteral protein solutions |
| CA3223313A1 (en) | 2021-06-23 | 2022-12-29 | Eli Lilly And Company | Methods of using and compositions including an incretin analog |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155812A0 (en) | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
| DK1641823T3 (da) | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| DK1831252T3 (da) | 2004-12-22 | 2009-10-05 | Lilly Co Eli | GLP-1 analog fusionsproteinformuleringer |
| ATE499088T1 (de) * | 2007-07-10 | 2011-03-15 | Lilly Co Eli | Glp-1-fc fusionsprotein-formulierung |
| AR100639A1 (es) * | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| WO2016168388A2 (en) * | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| CA3065295C (en) | 2017-06-01 | 2023-08-29 | Eli Lilly And Company | Dulaglutide for the treatment of chronic kidney disease |
-
2018
- 2018-11-13 KR KR1020207014456A patent/KR102589234B1/ko active Active
- 2018-11-13 PH PH1/2020/550795A patent/PH12020550795A1/en unknown
- 2018-11-13 CN CN202510640885.XA patent/CN120478602A/zh active Pending
- 2018-11-13 CR CR20200202A patent/CR20200202A/es unknown
- 2018-11-13 BR BR112020007817-4A patent/BR112020007817A2/pt not_active Application Discontinuation
- 2018-11-13 AU AU2018372709A patent/AU2018372709B2/en active Active
- 2018-11-13 UA UAA202002355A patent/UA127588C2/uk unknown
- 2018-11-13 PE PE2020000547A patent/PE20200847A1/es unknown
- 2018-11-13 SG SG11202003687RA patent/SG11202003687RA/en unknown
- 2018-11-13 EA EA202090971A patent/EA202090971A1/ru unknown
- 2018-11-13 EP EP18812499.4A patent/EP3713593A2/en active Pending
- 2018-11-13 MA MA050798A patent/MA50798A/fr unknown
- 2018-11-13 KR KR1020227035115A patent/KR20220146656A/ko not_active Ceased
- 2018-11-13 MX MX2020005231A patent/MX2020005231A/es unknown
- 2018-11-13 CN CN201880075369.5A patent/CN111356472A/zh active Pending
- 2018-11-13 JP JP2020525974A patent/JP7221956B2/ja active Active
- 2018-11-13 IL IL274563A patent/IL274563B2/en unknown
- 2018-11-13 WO PCT/US2018/060716 patent/WO2019103875A2/en not_active Ceased
- 2018-11-13 US US16/763,269 patent/US11576950B2/en active Active
-
2020
- 2020-05-12 CL CL2020001252A patent/CL2020001252A1/es unknown
- 2020-05-20 EC ECSENADI202026436A patent/ECSP20026436A/es unknown
- 2020-05-21 JO JOJO/P/2020/0126A patent/JOP20200126B1/ar active
- 2020-06-01 DO DO2020000104A patent/DOP2020000104A/es unknown
-
2022
- 2022-02-01 JP JP2022014339A patent/JP7818412B2/ja active Active
- 2022-05-18 AU AU2022203372A patent/AU2022203372B2/en active Active
-
2023
- 2023-01-04 US US18/149,982 patent/US20240189394A1/en active Pending
-
2024
- 2024-02-16 JP JP2024021637A patent/JP2024056908A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weir | Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents | |
| JP2022062153A5 (https=) | ||
| Kovanecz et al. | Long-term continuous sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats | |
| de Bem et al. | Antidiabetic effect of Euterpe oleracea Mart.(açaí) extract and exercise training on high-fat diet and streptozotocin-induced diabetic rats: A positive interaction | |
| JP7093669B2 (ja) | 即効型インスリン組成物 | |
| JP2021502379A5 (https=) | ||
| Ding et al. | Adiponectin protects rat myocardium against chronic intermittent hypoxia-induced injury via inhibition of endoplasmic reticulum stress | |
| Donald et al. | Para-aminosalicylic acid: the return of an old friend | |
| JP2018111728A5 (https=) | ||
| US20200179375A1 (en) | Formulations of oxabicycloheptanes and oxabicycloheptenes | |
| JP2018138578A5 (https=) | ||
| Vilay et al. | Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis | |
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| Wenk et al. | The New World Health Organization recommendations on perioperative administration of oxygen to prevent surgical site infections: a dangerous reductionist approach? | |
| JP2016539921A5 (https=) | ||
| JP7374163B2 (ja) | 急性肝不全及び他の肝毒性状態を治療及び／又はこれらから保護するための方法及び製剤 | |
| Ghali | Anemia and heart failure | |
| JP2022539077A5 (https=) | ||
| IL265761B1 (en) | Oral terlipressin compositions for use in treatment of ascites | |
| JP2019524888A5 (https=) | ||
| JP2020510045A5 (https=) | ||
| CN110461329A (zh) | 治疗血癌的PPARγ激动剂 | |
| JP2022501332A5 (https=) | ||
| WO2022228652A1 (en) | Means and method for treating viral infections | |
| US20090142298A1 (en) | Apolactoferrin Compositions and Methods for Their Use in the Treatment of Viral Hepatitis C |